2 Treatment of Bipolar Disorder in Cerebral Palsy: Challenges in

3 Antipsychotic Use

1

		X
Abstract		
	Abstract	Abstract

15 Cerebral palsy (CP) is a neurodevelopmental disorder that frequently coexists with psychiatric 16 conditions, including bipolar disorder. Treating bipolar disorder in this population poses significant 17 clinical challenges due to the clinical heterogeneity and comorbidities associated with CP. Adverse 18 effects of antipsychotics tend to have a more profound impact on the quality of life in individuals 19 with CP compared to the general population. Therefore, they represent a more serious clinical 20 concern.

This article aims to highlight the challenges of choosing antipsychotics for managing bipolar disorder in CP patients. To our knowledge, this topic has not been previously addressed in the literature. We propose that the antipsychotic selection should be guided by individual clinical characteristics, including CP subtype, mobility status, affected limbs, body mass index (BMI), and pre-existing orthopedic conditions. Personalized treatment may help providers better balance the risks of extrapyramidal symptoms and metabolic syndrome, thereby improving therapeutic outcomes and overall quality of life for this overlooked patient population.

28 KEYWORDS: CEREBRAL PALSY, ANTIPSYCHOTICS, EXTRAPYRAMIDAL SYMPTOMS, 29 METABOLIC SYNDROME, WEIGHT GAIN

- 30
- 31 32
- 33 34
- 35 36

- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53

54

55 Background

- 56
- 57 Cerebral palsy (CP) is a severe neurodevelopmental disorder that affects 3 out of every 1,000 live
- 58 births. In this disorder, an injury to the motor segment of the brain leads to movement disorders in
- 59 patients. These disorders are classified into three main types: spastic (muscle contractions), 60 dyskinatic (involuntary uncontrolled movements) and stavic (near coordination)
- 60 dyskinetic (involuntary, uncontrolled movements), and ataxic (poor coordination).
- 61 Spastic CP is the most prevalent form, and it affects approximately 80% of patients. Based on 62 which limbs are affected, it can be further actegorized as hemiplorie (one side of the hedy) diplorie
- which limbs are affected, it can be further categorized as hemiplegic (one side of the body), diplegic
 (both legs), or quadriplegic (all four limbs). Common clinical features of spastic CP include
- 64 increased deep tendon reflexes, tremors, hypertonia, muscle weakness, a characteristic scissors gait,
- 65 and toe walking.
- 66 The dyskinetic type, present in about 10–20% of patients, is associated with extrapyramidal
- 67 symptoms such as athetosis and dystonia. Athetosis is slow, snakelike, writhing movements,
- 68 particularly in the fingers, which exacerbate during periods of stress. Dystonia is an involuntary,
- 69 sustained muscle contraction.
- 70 The rarest form is ataxia, which affects 5–10% of individuals with CP. It impairs balance and
- coordination; patients often exhibit wide-based gait and intention tremors. Some patients may also present with mixed-type CP, displaying features from multiple categories 1, 2
- 73 Depending on the severity of the disorder, various comorbidities may occur: intellectual disability,
- ⁷⁴ inability to walk or speak, epilepsy, hip displacement, and incontinence.³
- 75
- 76 Cerebral palsy (CP) is caused by disturbances in fetal brain development. The risk factors
- associated with CP include placental abruption, uterine rupture, intrauterine infections, prematurity,
- maternal fever during pregnancy, congenital anomalies, complications related to multiple
 gestations, and birth asphyxia.
- 80 Cortical neurogenesis occurs during early gestation, particularly up to 24 weeks. Disruptions in this
- 81 developmental process due to genetic abnormalities, intrauterine infections, or exposure to toxic 82 agents can lead to structural brain abnormalities.
- 83 In the later stages of pregnancy, myelination, axonal and dendritic growth, and synapse formation
- 84 occur. At this stage, ischemia and hypoxia contribute to the development of CP.
- 85
- It is well recognized that having CP significantly reduces individuals' quality of life and leads to
- 87 considerable psychological distress, resulting in anxiety and depression. Research has shown that
- the prevalence of psychiatric disorders in CP patients is remarkably higher than in the general
- 89 population, except for substance use disorders. Having intellectual disability further increases the
- 90 prevalence of severe psychiatric conditions, such as psychotic disorders and bipolar disorder. On
- the other hand, among individuals with CP, those without intellectual disability have appeared to
 have an elevated risk of developing anxiety and depressive disorders.⁴
- 93 According to one study, attention-deficit/hyperactivity disorder (ADHD) is the most common
- 94 psychiatric comorbidity in this population.⁵ Other frequently reported psychiatric disorders in

- 95 individuals with CP include obsessive-compulsive disorder, oppositional defiant disorder,
- 96 schizophrenia, bipolar disorder, and generalized anxiety disorder.^{4, 6} These findings highlight the
- 97 importance of regular mental health evaluations in individuals with CP. Unfortunately,
- 98 communication difficulties commonly seen in this population may cause psychiatric symptoms to
- be overlooked, which can lead to delays in diagnosis and worsening of mental health conditions.

101 Bipolar disorder is a mood disorder characterized by manic and depressive episodes. A manic

102 episode is defined by an elevated or irritable mood, heightened energy, inflated self-esteem,

103 decreased need for sleep, and racing thoughts lasting for at least a week. In contrast, a depressive 104 episode is composed of feelings of worthlessness, anhedonia, and disturbances in appetite and sleep

⁷ Approximately 1.2% of the general population is affected by bipolar disorders. However, it affects

2.1% of the CP patients and 2.7% of the CP patients who also have intellectual disability.⁴
 Treatment of bipolar disorder in patients with CP requires special attention due to possibly more

- severe extrapyramidal and metabolic adverse effects. In this article, we will explore the difficulties and limitations in the management of bipolar disorder in patients with Cerebral Palsy.

- 147 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158

159 **Bipolar Disorder Management in Cerebral Palsy** 160

161 Bipolar treatments available and approved by the FDA are mainly antidepressants for bipolar

162 depression, as well as antipsychotics and mood stabilizers for mania, depression, and maintenance. Compared with mood stabilizing medications, second-generation antipsychotics have a faster onset 163

of action, making them a first-line treatment for severe acute manic symptoms. Traditional mood 164 165 stabilizers, such as lithium, valproate, and carbamazepine, are also effective in treating active

mania. For long-term treatment, most of the second-generation antipsychotics (except lurasidone 166 167 and paliperidone), lithium, valproate, and lamotrigine are approved.⁸

168

Patients with CP may be prone to neurologic adverse effects due to underlying brain conditions. as 169

- 170 suggested in various studies. One study shows serotonin syndrome in CP patients with atypical
- drugs like SSRI monotherapy, lithium, and olanzapine. Serotonin syndrome is characterized by 171
- clonus, diaphoresis, hyperreflexia, hypertonia, and hyperthermia, and typically occurs with two or 172 173
- more serotonergic agents.⁹ Another study indicated that administering haloperidol to a patient with
- cerebral palsy (CP) resulted in destructive motor and cognitive effects. The patient became 174
- 175 unresponsive and showed no spontaneous movement. The study suggested that decreased levels of
- 176 dopamine are observed in animal studies of cerebral hypoxia in the developing brain, and given that 177 cerebral hypoxia is one of the main pathologies of CP, this could lead to significantly reduced
- 178 baseline dopamine levels in individuals with CP. Consequently, this makes them more susceptible
- to the effects of pharmacological dopamine blockade.¹⁰ 179
- Also, approximately half of the patients with CP have an intellectual disability.³ As having an 180
- organic brain disorder and intellectual disability is a risk factor for Neuroleptic Malignant 181
- Syndrome, when these individuals have an affective disorder, they are at an increased risk for it.¹¹ 182
- 183 Therefore, when prescribing antipsychotics to these patients, it is essential to consider these risks.
- 184
- 185 Using antipsychotics for patients with cerebral palsy (CP) requires careful consideration. Due to the
- 186 underlying movement disorder, the risk of experiencing extrapyramidal side effects increases.
- 187 Extrapyramidal symptoms (EPS) include akathisia (motor restlessness), dystonia (sustained
- muscular contraction), parkinsonism (bradykinesia, rigidity, tremor), tardive dyskinesia (late-onset 188
- choreiform movements), and tardive dystonia (late-onset dystonia).¹² 189
- 190 CP affects motor control, and EPS can exacerbate movement difficulties, making daily activities
- 191 even more challenging. The following examples illustrate how EPS may manifest in this 192 population.
- 193 Dystonia may increase muscle tone and worsen the already present spasticity in these patients,
- 194 leading to further stiffness. For patients with ataxic CP, impaired balance combined with EPS
- symptoms such as parkinsonism could significantly elevate the risk of falls and related injuries.¹³ 195
- 196 Tardive dyskinesias, including tardive dystonia, are persistent, late-onset adverse effects that may
- last up to years, and they occur with long-term use of antipsychotics. ¹² Tardive dyskinesia mainly 197
- affects the orofacial muscles but can also involve the limbs. This limb involvement may contribute 198

to gait disturbances that already exist in CP patients.^{3, 14} Tardive dystonia can affect multiple body 199 areas, including neck musculature, trunk, limbs, and oromandibular muscles,¹⁴ Oromandibular 200 201 dystonia (OMD) is an involuntary contraction of the jaw, tongue, and facial muscles. These issues 202 can worsen speech disorders and swallowing difficulties that are already common in CP patients. 203 Speech disorders in OMD can be summarized by signatism (difficulty pronouncing sibilant 204 sounds) and poor phoneme linkage (difficulty connecting speech sounds), which causes reduced 205 fluency. Dysphonia or difficulty in vocalization is also common in OMD. These adverse effects of EPS make social interactions more challenging, causing anxiety in patients.¹⁵ Additionally, having 206 EPS significantly lowers the quality of life¹⁶ and is the direct cause of medication discontinuation 207 for many patients. Along with the fact that psychiatric patients are poor historians, the 208 communication problems with CP patients can cause EPS to go undiagnosed.¹⁷ Furthermore. 209 symptoms like akathisia, akinesia, and acute dystonia may resemble common psychiatric 210

- 211 symptoms, complicating the diagnosis of EPS.¹⁷
- 212

EPS arises from the dopamine D2 receptor antagonist activity of drugs in the striatum. Research 213 214 suggests a D2 receptor occupancy rate of 80% or higher is associated with a high likelihood of 215 demonstrating EPS. An occupancy rate between 70% and 80% indicates a moderate probability of 216 EPS, while an occupancy rate below 70% is generally not associated with EPS. Mainly, the goal is 217 to maintain sufficient D2 antagonism to achieve an antipsychotic effect while minimizing injury to 218 the D2 dopamine system to avoid EPS. Second-generation antipsychotics (SGAs) such as 219 aripiprazole, olanzapine, risperidone, olanzapine, and quetiapine typically have a superior EPS 220 profile compared to first-generation antipsychotics (FGAs). High-potency FGAs like haloperidol 221 are more likely to cause EPS due to their highest occupancy rates. Among SGAs, research 222 demonstrates that risperidone has a more unfavorable side effect profile than the other options. In 223 contrast, quetiapine and clozapine have the lowest D2 occupancy rates, so they exhibit the lowest 224 incidence of EPS compared to other SGAs.¹⁷

225

In order to reduce this occupancy, some medications that indirectly augment dopamine activity
through serotonin antagonism (high 5-HT2/D2 ratio) and partial D2 agonism are being tested.
While these diminish EPS liability, they do not eliminate EPS altogether. Both risperidone and
ziprasidone exhibit strong serotonin antagonist activity; however, this is insufficient to prevent EPS

in the case of risperidone. For ziprasidone, this assertion is valid to a lesser extent. Patients who

- switched from conventional antipsychotics or risperidone to ziprasidone experienced fewer EPS
 after six weeks of ziprasidone treatment. That said, the EPS risk of risperidone below the doses of 6
- mg per day is low. Across a therapeutic dose range of 0.5–16 mg per day, there is a significant
- 234 linear correlation between the dose of risperidone and the incidence of EPS, which is still associated 235 with fewer adverse effects than high-potency FGAs.
- Both quetiapine and clozapine have significant 5-HT2A antagonism, but they also possess unique
 properties that reduce D2 antagonism.
- Aripiprazole has a very low EPS liability despite having a striatal D2 occupancy rate between 80%
- and 90%. This phenomenon can be attributed to the partial agonist properties of aripiprazole.
- 240 Specifically, the agonist activity is 30%, which is sufficient to maintain normal dopaminergic motor 241 activity. ^{17, 18}
- 242
- According to a meta-analysis on EPS associated with antipsychotics, quetiapine is associated with
- the least incidence of dystonia (1.4%), paliperidone is associated with the least incidence of
- akathisia (3.3%), while clozapine is associated with the least incidence of parkinsonism (3.7%) and tramper (0.2%). Heleneridal above users high rates of these side effects are price from 1.6% + 2.4% ¹⁹
- tremor (0.2%). Haloperidol shows very high rates of these side effects, ranging from 16% to 24%.¹⁹
- 247 Clozapine is typically reserved for treatment-resistant patients due to the serious side effect of
- agranulocytosis. However, some studies suggest that clozapine may lead to symptom resolution for
 tardive dyskinesia, especially in cases of tardive dystonia. ^{12, 16}
- 250

- 251 Children with disabilities face a higher risk of obesity compared to the general population of
- children. Patients with diplegic or quadriplegic CP may be wheelchair-bound, and the adverse
- effects of antipsychotics, such as metabolic syndrome and weight gain, should be considered more
 seriously in this population. Reduced mobility, restricted social participation, and an increase in
 depressive symptoms significantly contribute to weight gain within this group.
- 256 In patients with limited mobility, the incidence of pressure ulcers increases. Although being obese
- may provide some protection against pressure ulcers, extremely obese individuals (BMI>40) have
- higher rates of pressure ulcers compared to patients with a normal weight. Overall, both being
- 259 underweight and extremely obese are risk factors for developing pressure ulcers.²²
- 260 Studies indicate that individuals with cerebral palsy (CP) who carry excess weight around the belly
- 261 experience gait problems, resulting in slower walking speeds, shorter step lengths, and reduced
- ranges of joint motion. They also exhibit decreased moments and powers during movement.²³
 Furthermore, 36% of CP patients are affected by hip disorders. Spasticity can contribute to hip pain
 and dislocation, and as individuals gain weight, the compressive and shear forces on the hip during
 walking increase. This additional load on the hip joint raises the risk of developing hip pain and
- related pathologies. ^{3, 24} Moreover, increased weight can heighten the need for caregiver assistance
 in daily activities, making their responsibilities more challenging.²⁰
- 268

A meta-analysis examining weight gain as an adverse effect of antipsychotics indicates that olanzapine is associated with the most clinically relevant weight gain within six weeks of treatment,

- affecting 24.1% of patients compared to 1.4% on placebo. Following olanzapine,
- risperidone results in weight gain for 16.8% of patients, compared to 2.9% on placebo, while

aripiprazole shows a 16.8% weight gain versus 7% on placebo. Quetiapine is associated with weight

- 274 gain in 12.5% of patients compared to 6% on placebo.²⁵
- 275

In another comprehensive study, clozapine and olanzapine were identified as having the highest risk
of weight gain, with olanzapine at the top of the list. Mid-risk antipsychotics include asenapine,
risperidone, paliperidone, and quetiapine. The antipsychotics associated with the lowest risk of
weight gain are aripiprazole, lurasidone, and ziprasidone. Haloperidol is also noted to cause less
weight gain than second-generation antipsychotics (SGAs).

- 281 282
- 282

284 Conclusion

285 We aimed to demonstrate how these adverse effects of antipsychotic medications impact the lives of 286 cerebral palsy patients, and which medications carry a higher risk. Also, we sought to highlight that 287 the treatment of bipolar disorder in patients with cerebral palsy should be customized by 288 considering their specific clinical characteristics. These characteristics can include the subtype of 289 CP (spastic, ataxic, or dyskinetic), which limb is affected, wheelchair dependency, the presence of 290 pre-existing hip disorders, and their Body Mass Index (BMI). By considering the patient profile, physicians can better prioritize whether to be more cautious about extrapyramidal or metabolic 291 292 adverse effects of antipsychotics. This approach will help choose the most appropriate medication 293 and optimize outcomes for this population. To our knowledge, this topic has not been addressed 294 previously in the literature, and further research is essential to guide clinical decision-making in this 295 overlooked group.

- 296
- 297
- 298
- 299
- 300

301		
302		
303		
304		
305		
306		
307		
308		
309		
310		
311		
312		
313		
314		
315		
316	Re	ferences
317	Itt	
318	1	Unadhyay I. Tiwari N. & Ansari M. N. (2020). Cerebral palsy: Actiology nathonhysiology
310	1	and therapeutic interventions <i>Clinical and Experimental Pharmacology & Physiology</i> , 47(12)
320		1801 1001 https://doi.org/10.1111/1/1/0.1681.13370
320	\mathbf{r}	$\frac{1091-1901}{1000} \frac{\text{mups.}/(001.01g/10.1111/1440-1001.15577)}{10000}$
321	Z	Kingger, K. W. (2000). Cerebrar parsy. An overview. American Family Physician, 75(1), 91–
322	2	100. Vitailaas K. Daltan H. & Braich D. (2020). Carabral ralay An avanian. Amaria n. Envilu
323 324	3	<i>Physician</i> 101(4) 212 220
324 2 25	1	McMorris C A Lake L Debrenovski K McCorry C Lin E Wilton D Lungky V &
323 226	4	MCMONTS, C. A., Lake, J., Dooranowski, K., McGarry, C., Lin, E., Witton, D., Lunsky, T., & Dalach, B. (2021). Development discondensing adults with combinal polacy. <i>Basagnah in</i>
320 227		Daugh, R. (2021). Psychiatric disorders in adults with cerebrai paisy. <i>Research in</i>
327	~	Developmental Disabilities, 111, 103859. https://doi.org/10.1016/j.ridd.2021.103859
328	3	Bjorgaas, H. M., Hysing, M., & Elgen, I. (2012). Psychiatric disorders among children with
329	_	cerebral palsy at school starting age. Research in Developmental Disabilities, 33(4), 1287–1293.
330	6	Downs, J., Blackmore, A. M., Epstein, A., Skoss, R., Langdon, K., Jacoby, P., Whitehouse, A.
331		J. O., Leonard, H., Rowe, P. W., & Glasson, E. J.; Cerebral Palsy Mental Health Group. (2018).
332		The prevalence of mental health disorders and symptoms in children and adolescents with
333		cerebral palsy: A systematic review and meta-analysis. Developmental Medicine & Child
334		<i>Neurology</i> , 60(1), 30–38.
335	7	American Psychiatric Association. (2013). Diagnostic and statistical manual of mental
336		disorders (5th ed., pp. 123–126). American Psychiatric Publishing.
337	8	Goes, F. S. (2023). Diagnosis and management of bipolar disorders. <i>BMJ</i> , 381, e073591.
338	9	Schindzielorz, A. (2022). Increased sensitivity to serotonin syndrome in cerebral palsy. <i>Case</i>
339		Reports in Psychiatry, 2022(9), 1–3.
340	10	Mortimer, D., Gelfius, C. D., & Potts, M. A. (2013). Deleterious cognitive and motoric effects
341		of haloperidol in an adolescent with cerebral palsy: A case report. <i>PM&R</i> , 5(12), 1077–1080.
342	11	Viejo, L. F., Morales, V., Puñal, P., Pérez, J. L., & Sancho, R. A. (2003). Risk factors in
343		neuroleptic malignant syndrome: A case-control study. Acta Psychiatrica Scandinavica, 107(1),
344		45–49.
345	12	Pierre, J. M. (2005). Extrapyramidal symptoms with atypical antipsychotics: Incidence,
346		prevention and management. Drug Safety, 28(3), 191–208.
347	13	Chan, CH., Gau, S. SF., Chan, HY., Tsai, YJ., Chiu, CC., Wang, SM., & Huang, ML.
348		(2013). Risk factors for falling in psychiatric inpatients: A prospective, matched case-control
349		study. Journal of Psychiatric Research, 47(8), 1088–1094.
350	14	Van Harten, P. N., & Kahn, R. S. (1999). Tardive dystonia. Schizophrenia Bulletin, 25(4), 741-
351		748.

- Kreisler, A., Verpraet, A.-C., Veit, S., Pennel-Ployart, O., Béhal, H., Duhamel, A., & Destée, A.
 (2016). Clinical characteristics of voice, speech, and swallowing disorders in oromandibular
 dystonia. *Journal of Speech, Language, and Hearing Research, 59*(5), 940–949.
- 355 16 Adrianzén, C., Arango-Dávila, C., Martínez Araujo, D., Ruíz, I., Walton, R. J., Dossenbach, M.,
 356 & Karagianis, J.(2010). Relative association of treatment-emergent adverse events with quality
 357 of life of patients with schizophrenia: Post hoc analysis from a 3-year observational
 358 study. *Human Psychopharmacology: Clinical and Experimental*, 25(6), 439–447.
- Weiden, P. J. (2007). EPS profiles: The atypical antipsychotics are not all the same. *Journal of Psychiatric Practice*, *13*(1), 13–24.
- 18 Natesan, S., Reckless, G. E., Nobrega, J. N., Fletcher, P. J., & Kapur, S. (2006). Dissociation
 between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing
 aripiprazole to other antipsychotics in animal models. *Neuropsychopharmacology*, *31*(9), 1854–
 1863.
- Martino, D., Karnik, V., Osland, S., Barnes, T. R. E., & Pringsheim, T. M. (2018). Movement
 disorders associated with antipsychotic medication in people with schizophrenia: An overview
 of Cochrane reviews and meta-analysis. *The Canadian Journal of Psychiatry*, 63(11), 730–739.
- 20 Dogruoz Karatekin, B., Kacar, G., & Icagasioglu, A. (2023). Obesity in ambulatory children
 with cerebral palsy in Turkey: A cross-sectional study. *Journal of Pediatric Rehabilitation Medicine*, 16(1), 195–202.
- 371 21 Kiernan, D., Nikolopoulou, C., & Brady, K. (2021). Prevalence of overweight and obesity in
 372 Irish ambulant children with cerebral palsy. *Irish Journal of Medical Science*, *190*(1), 225–231.
- 22 Hyun, S., Li, X., Vermillion, B., Newton, C., Fall, M., Kaewprag, P., Moffatt-Bruce, S., &
 24 Lenz, E. R. (2014). Body mass index and pressure ulcers: Improved predictability of pressure
 25 ulcers in intensive care patients. *American Journal of Critical Care*, 23(6), 494–501.
- Meyns, P., Van Gestel, L., Bar-On, L., Goudriaan, M., Wambacq, H., Aertbeliën, E.,
 Bruyninckx, H., Molenaers, G., De Cock, P., Ortibus, E., & Desloovere, K. (2016). Children
 with spastic cerebral palsy experience difficulties adjusting their gait pattern to weight added to
 the waist, while typically developing children do not. *Frontiers in Human Neuroscience, 10*,
 657.
- 24 Lerner, Z. F., & Browning, R. C. (2016). Compressive and shear hip joint contact forces are
 affected by pediatric obesity during walking. *Journal of Biomechanics*, 49(9), 1547–
 1553. <u>https://doi.org/10.1016/j.jbiomech.2016.03.033</u>
- Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020). Update on weightgain caused by antipsychotics: A systematic review and meta-analysis. *Expert Opinion on Drug Safety*, 19(3), 295–314.
- Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2015). Weight gain and antipsychotics: A
 drug safety review. *Expert Opinion on Drug Safety*, 14(1), 73–96.
- 389 27 Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-
- generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. *The Lancet*, 373(9657), 31–41.